Get Your Own Businessabc AI Visibility ID
Boost AI visibility, credibility, and discoverability
Arvinas was founded in 2013 by Princeton University professor Craig Crews, who introduced the concept of protein degradation as a novel approach to drug discovery. In that same year, the first round of venture capital funding was secured and work began on the revolutionary PROTAC technology. In 2017, Arvinas entered into a collaboration with Pfizer to develop gene-editing drugs. In 2020, Arvinas went public on the Nasdaq and raised more than $425 million.
